The Effect of Inhaled Steroids on the Linear Growth of Children with Asthma: a Meta-Analysis

Total Page:16

File Type:pdf, Size:1020Kb

The Effect of Inhaled Steroids on the Linear Growth of Children with Asthma: a Meta-Analysis The Effect of Inhaled Steroids on the Linear Growth of Children With Asthma: A Meta-analysis Paul J. Sharek, MD, MPH, and David A. Bergman, MD ABSTRACT. Objective. To determine whether in- restricted activity days in children and 2.2 million haled steroid therapy causes delayed linear growth in pediatrician visits annually.2 Between 1980 and 1993, children with asthma. mortality rates increased 118% and hospitalization Data Sources. Medline (1966–1998), Embase (1980– rates increased 28% for children with asthma.3 Chil- 1998), and Cinahl (1982–1998) databases and bibliogra- phies of included studies were searched for randomized, dren with asthma miss 3 times as much school as 4 controlled trials of inhaled steroid therapy in children children without asthma, and the overall cost of with asthma that evaluated linear growth. severe asthma in childhood was estimated at $18 000 Study Selection. Studies were included if they met per child per year.5 With prevalence rates increasing the following criteria: subjects 0 to 18 years of age with from 3.1% in 1981 to 6.9% in 1994,6 asthma is the the clinical diagnosis of asthma; subjects randomized to most common chronic disease in childhood. inhaled beclomethasone, budesonide, flunisolide, fluti- These data are striking in light of increased under- casone, or triamcinolone versus a nonsteroidal inhaled control for a minimum of 3 months; single- or double- standing of the pathophysiology of asthma. Recently, blind; and outcome convertible to linear growth velocity. for example, the vital role of the inflammatory pro- English- and non–English-language trials were included. cess in asthma has been recognized and empha- Data Extraction. Data were extracted using a priori sized.7,8 Studies over the past 15 years have revealed guidelines. Methodologic quality was assessed indepen- improvement in multiple asthma outcomes in pa- dently by both authors. Outcome was extracted as linear tients treated with inhaled and systemic steroids.9–16 growth velocity. Inhaled steroids are now recommended for all chil- Results. Included trials were subgrouped by inhaled 8 steroid. The beclomethasone subgroup, with 4 studies dren with chronic persistent asthma. Evidence that and 450 subjects, showed a decrease in linear growth inhaled steroids effectively control asthma in chil- velocity of 1.51 cm/year (95% confidence interval: dren and minimize pulmonary damage has resulted 1.15,1.87). The fluticasone subgroup, with 1 study and 183 in a dramatic increase in the use of inhaled steroids subjects, showed a decrease in linear growth velocity of in the control of asthma in children. .43 cm/year (95% confidence interval: .01,.85). Sensitivity Despite clear benefits, there are risks to the use of analysis in the beclomethasone subgroup, which evalu- inhaled steroids in children with asthma. These risks ated study quality, mode of medication delivery, control medication, and statistical model, showed similar results. include altered hypothalamic-pituitary axis function- 17–21 Conclusions. This meta-analysis suggests that moder- ing with possible resultant delayed linear ate doses of beclomethasone and fluticasone in children growth.22–27 The recent Food and Drug Administra- with mild to moderate asthma cause a decrease in linear tion mandate to require labels on inhaled and intra- growth velocity of 1.51 cm/year and .43 cm/year, respec- nasal corticosteroids warning of a potential reduc- tively. The effects of inhaled steroids when given for >54 tion in linear growth in children depicts this weeks, or on final adult height, remain unknown. concern.28 Attempts to determine the effect of in- Pediatrics 2000;106(1). URL: http://www.pediatrics.org/ cgi/content/full/106/1/e8; asthma, children, growth, in- haled steroids on linear growth in children with haled steroid, beclomethasone, fluticasone. asthma are confounded by poorly controlled asthma, reduced growth rates before puberty, delayed pu- berty, and frequent use of growth-suppressing sys- ABBREVIATIONS. RCT, randomized, controlled trial; WMD, 29–31 weighted mean difference; CI, confidence interval. temic steroids. The 1 previous systematic review evaluating growth in asthmatic children using in- haled steroids concluded inhaled steroids had no 27 sthma is a chronic inflammatory disease of effect. Recent randomized, controlled trials (RCTs), 22–25 the airways affecting an estimated 4.8 million however, conflict with this conclusion. children younger than 18 years of age in the As a result of previous studies with conflicting A 1 Ͼ results, the publication of recent data that could im- United States. Asthma is responsible for 28 million pact the conclusions of the only published meta- From the Division of General Pediatrics, Department of Pediatrics, Stanford analysis, and persistent uncertainty regarding the University School of Medicine, Palo Alto, California. effect of inhaled steroids on the linear growth of Received for publication Oct 18, 1999; accepted Feb 16, 2000. children with asthma, we undertook this systematic Reprint requests to (P.J.S.) Lucile Packard Children’s Hospital at Stanford, review. The aim of this systematic review was to 725 Welch Rd, Palo Alto, CA 94304. E-mail: [email protected] PEDIATRICS (ISSN 0031 4005). Copyright © 2000 by the American Acad- determine whether inhaled steroid use is associated emy of Pediatrics. with growth suppression in children with asthma. http://www.pediatrics.org/cgi/content/full/106/1/Downloaded from www.aappublications.org/newse8 by guest PEDIATRICSon September 28, Vol.2021 106 No. 1 July 2000 1of7 METHODS exclusion criteria. The number of withdrawals and reasons for withdrawal in each treatment arm were recorded. Trial Identification Relevant RCTs in all languages were identified as follows. First, Data Analysis 3 databases were systematically searched for studies on asthma: 1) Medline, from 1966 to 1998; 2) Embase, from 1980 to 1998; and Meta-analysis was performed on all trials that met the inclusion 3) Cinahl, from 1982 to 1998. In Medline, full-text and Medical criteria. This meta-analysis was conducted using the Cochrane Subject Heading terms were searched for using “asthma*”; in Collaboration software program, Review Manager, Version 3.1 Embase, a full-text and keyword search was performed using (Cochrane Collaboration, Oxford, UK). The mean linear growth “asthma*”; and in Cinahl, a full-text and Medical Subject Heading velocity of subjects treated with inhaled steroids was compared terms were searched using “asthma*.” The identified records were with the mean linear growth velocity of subjects treated with a then imported into a Pro-Cite database. Within this asthma data- nonsteroidal preparation, and the results were expressed as the base, we searched across all fields to identify possible RCTs using difference in mean linear growth velocity. A difference of the Ͻ the terms: “random*” or “trial*” or “placebo*” or “comparative means (mean difference) of 0 indicates that inhaled steroids have study” or “controlled study” or “double-blind” or “double blind” a decelerating effect on linear growth compared with the control or “single-blind” or “single blind.” The results of this search were medication. The mean difference was calculated for each individ- 36 downloaded into a new database, which was searched on all fields ual trial, and using the fixed effects model a summary weighted for “steroid*” or “corticosteroid*” or “glucocorticoid*” or “budes- mean difference (WMD) was determined. The weighting method onide” or “flunisolide” or “fluticasone” or “triamcinolone” or used defines the weight of the trial as the inverse of the variance 23 “beclomethasone” and “inhal*” and “child*” or “infan*” or “ado- of the mean difference. One study did not report standard devi- lescen*” or “pediatr*” or “paediatr*.” Each abstract was then ations for the linear growth velocities of each group and, therefore, reviewed and annotated as: 1) RCT, 2) clearly not RCT, or 3) after repeated attempts to contact the author were unsuccessful, unclear. All references identified as RCTs or unclear were in- we estimated the standard deviations assuming equal deviation in cluded for title and abstract review. All non-English language the intervention and control groups. Statistical heterogeneity 37,38 39 publications that could not be excluded by title or abstract were among trials was assessed by the Q test and graphically. translated and evaluated in the same manner as English language Summary WMDs were calculated using the random effects model 38 publications. of DerSimonian and Laird for comparison between statistical Each title and abstract from the search results was reviewed models. with respect to the inclusion criteria. Any trials not specifically Sensitivity analyses were conducted to assess the robustness of removed for failure to meet the inclusion criteria based on title or the meta-analysis by comparing WMDs among groups redefined abstract were reviewed in detail. Reference lists of all identified by: 1) excluding trials of lower methodological quality (Jadad Ͻ Ͻ 33,40 RCTs were checked to identify relevant citations. Personal contact score 4; randomization score A), 2) excluding trials using with colleagues and researchers working in the field of asthma the metered-dose inhaler method of medication delivery, and 3) was made to identify relevant trials and any unpublished data. excluding trials using nonplacebo, control medication. A funnel graph of the study weight versus the mean difference of lengths was
Recommended publications
  • Antiviral Effect of Budesonide Against SARS-Cov-2
    viruses Communication Antiviral Effect of Budesonide against SARS-CoV-2 Natalie Heinen 1 , Toni Luise Meister 1 , Mara Klöhn 1 , Eike Steinmann 1, Daniel Todt 1,2 and Stephanie Pfaender 1,* 1 Department of Molecular and Medical Virology, Ruhr-University Bochum, 44801 Bochum, Germany; [email protected] (N.H.); [email protected] (T.L.M.); [email protected] (M.K.); [email protected] (E.S.); [email protected] (D.T.) 2 European Virus Bioinformatics Center (EVBC), 07743 Jena, Germany * Correspondence: [email protected]; Tel.: +49-234-32-23189 Abstract: Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME TRELEGY ELLIPTA 100/62.5/25 fluticasone furoate (100 micrograms)/umeclidinium (as bromide) (62.5 micrograms)/vilanterol (as trifenatate) (25 micrograms), powder for inhalation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 92 micrograms fluticasone furoate, 55 micrograms umeclidinium (equivalent to 65 micrograms umeclidinium [as bromide]) and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 62.5 micrograms umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide) and 25 micrograms vilanterol (as trifenatate). Excipient with known effect: Each delivered dose contains approximately 25 milligrams of lactose (as monohydrate). For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for inhalation. White powder in a light grey inhaler (Ellipta) with a beige mouthpiece cover and a dose counter. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications TRELEGY ELLIPTA is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with a long- acting muscarinic receptor antagonist (LAMA) + long-acting beta2-receptor agonist (LABA) + inhaled corticosteroid (ICS). TRELEGY ELLIPTA should not be used for the initiation of COPD treatment. 4.2. Dose and method of administration Patients can be changed from their existing inhalers to TRELEGY ELLIPTA at the next dose. However it is important that patients do not take other LABA or LAMA or ICS while taking TRELEGY ELLIPTA. A stepwise approach to the management of COPD is recommended, including the cessation of smoking and a pulmonary rehabilitation program.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • FLONASE (Fluticasone Propionate) Nasal Spray Bacterial, Viral, Or Parasitic Infection; Ocular Herpes Simplex)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, These highlights do not include all the information needed to use contact dermatitis, rash) have been reported after administration of FLONASE safely and effectively. See full prescribing information for FLONASE nasal spray. Discontinue FLONASE nasal spray if such FLONASE. reactions occur. (5.3) • Potential worsening of infections (e.g., existing tuberculosis; fungal, FLONASE (fluticasone propionate) nasal spray bacterial, viral, or parasitic infection; ocular herpes simplex). Use with Initial U.S. Approval: 1994 caution in patients with these infections. More serious or even fatal course --------------------------- RECENT MAJOR CHANGES --------------------------- of chickenpox or measles can occur in susceptible patients. (5.4) • Hypercorticism and adrenal suppression may occur with very high Warnings and Precautions, Glaucoma and Cataracts (5.2) 1/2019 dosages or at the regular dosage in susceptible individuals. If such --------------------------- INDICATIONS AND USAGE ---------------------------- changes occur, discontinue FLONASE nasal spray slowly. (5.5) FLONASE nasal spray is a corticosteroid indicated for the management of the • Monitor growth of pediatric patients. (5.7) nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients ------------------------------ ADVERSE REACTIONS ------------------------------ aged 4 years and older. (1) The most common adverse reactions (>3%) are headache, pharyngitis, ----------------------- DOSAGE AND ADMINISTRATION ----------------------- epistaxis, nasal burning/nasal irritation, nausea/vomiting, asthma symptoms, For intranasal use only. Recommended starting dosages: and cough. (6.1) • Adults: 2 sprays per nostril once daily (200 mcg per day). (2.1) To report SUSPECTED ADVERSE REACTIONS, contact • Adolescents and children aged 4 years and older: 1 spray per nostril once GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or daily (100 mcg per day).
    [Show full text]
  • Asthma Medications
    Relievers / Rescue / Bronchodilators Asthma Short-acting Beta Agonists 2 Medications Ipratropium Bromide ProAir ProAir RespiClick Proventil Ventolin Xopenex albuterol sulfate albuterol sulfate dry powder albuterol sulfate albuterol sulfate levalbuterol tartrate 90mcg 90mcg 90mcg 90mcg 45mcg Teva Teva Merck GlaxoSmithKline Sunovion Atrovent* Combivent Respimat* ipratropium bromide ipratropium bromide 20mcg, 17mcg albuterol sulfate 100mcg Boehringer Ingelheim Boehringer Ingelheim Nebulized Albuterol Xopenex Inhalation Solution Xopenex Inhalation Solution Xopenex Inhalation Solution * Ipratropium bromide is not a recommended rescue inhaler albuterol sulfate levalbuterol HCl levalbuterol HCl levalbuterol HCl outside of use in the emergency room or urgent care but may, 2.5mg/3mL 0.31mg/3mL 0.63mg/3mL 1.25mg/3mL on occasion, be prescribed to supplement short-acting Beta 2 generic Sunovion Sunovion Sunovion agonists. Controllers Inhaled Corticosteroids (ICS): Metered-Dose Inhalers (MDI) Aerospan Alvesco Alvesco Asmanex Asmanex Flovent Flovent Flovent flunisolide ciclesonide ciclesonide mometasone furoate mometasone furoate fluticasone propionate fluticasone fluticasone propionate 80mcg 80mcg 160mcg 100mcg 200mcg 44mcg propionate 220mcg Meda Pharmaceuticals Sunovion Sunovion Merck Merck GlaxoSmithKline 110mcg GlaxoSmithKline GlaxoSmithKline Inhaled Corticosteroids (ICS): Dry Powder Inhalers(continued on back) QVAR QVAR beclomethasone beclomethasone dipropionate dipropionate 40mcg 80mcg ArmonAir RespiClick ArmonAir RespiClick ArmonAir RespiClick
    [Show full text]
  • Drug Class Review Nasal Corticosteroids
    Drug Class Review Nasal Corticosteroids Final Report Update 1 June 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Dana Selover, MD Tracy Dana, MLS Colleen Smith, PharmD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Marian McDonagh, PharmD, Principal Investigator, Drug Effectiveness Review Project Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ..........................................................................................................................5 Scope and Key Questions .......................................................................................................................7 METHODS ....................................................................................................................................9 Literature Search .....................................................................................................................................9
    [Show full text]
  • Steroids: the Good, the Bad and the Ugly!
    STEROIDS: THE GOOD, THE BAD AND THE UGLY! MICHAEL ZACHARISEN, MD. CONFLICT OF INTEREST, DISCLOSURES Conflict of interest: None Disclosures: I prescribe steroids and have for 31 years I will be discussing off label uses of steroids 1997 the first ICS OUTLINE • History of steroids in asthma • Steroids: Types, preparations, routes of administration • “The Good”: Benefits of steroids in asthma • “The Bad and the Ugly”: Risks and side effects of steroids in asthma • How to mitigate the risks of steroids when used in asthma DISEASES TREATED WITH CORTICOSTEROIDS Inflammatory • Asthma Autoimmune Connective Tissue • Anaphylaxis • Systemic Lupus erythematosus (Lupus) • Hypersensitivity pneumonitis • Sarcoid, Systemic sclerosis, MCTD • ABPA • Inflammatory Bowel Disease • Urticaria (hives) • Vasculitis, Myositis • Eczema • Bullous dermatitis Immune Suppression Other • Cancer • Adrenal insufficiency/Addison’s CONTRAINDICATIONS FOR SYSTEMIC STEROIDS Absolute Relative • Systemic fungal infection • Hypertension and Congestive Heart Failure • Herpes simplex keratitis • Psychosis or depression • Hypersensitivity • Active peptic ulcer disease • Active TB • Diabetes mellitus • Osteoporosis • Cataracts, glaucoma • Recent intestinal anastomoses HOW STEROIDS WORK At the cell level: • Suppress multiple inflammatory genes that are activated in asthmatic airways by reversing histone acetylation of the activated inflammatory genes • Induce apoptosis of eosinophils • Upregulate beta-receptors HISTORY OF STEROIDS FOR ASTHMA/ALLERGY • 1900: Cortisone discovered (not
    [Show full text]
  • Rectal Corticosteroids Versus Alternative Treatments in Ulcerative Colitis: a Meta-Analysis Gut: First Published As 10.1136/Gut.40.6.775 on 1 June 1997
    Gut 1997; 40: 775-781 775 Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut: first published as 10.1136/gut.40.6.775 on 1 June 1997. Downloaded from J K Marshall, E J Irvine Abstract medication consistently to the splenic Background-Clear strategies to optimise flexure,49 and a larger volume seems to allow the use of corticosteroids in ulcerative more proximal delivery.10 11 Rectal foam dis- colitis are lacking. seminates medication to the rectum and distal Aim-A meta-analysis was undertaken to descending colon,'2-16 whereas suppositories examine critically the role of rectal corti- coat only the rectum.'7 18 costeroids in the management of active Although studies of rectally administered distal ulcerative colitis. corticosteroids have reported fewer systemic Methods-AJl reported randomised con- adverse effects than with oral preparations, trolled trials were retrieved by searching plasma concentrations of prednisolone were the Medline and EMBASE databases and similar after administration of identical oral or the bibliographies of relevant studies. rectal doses.'9 20 Suppression of the hypo- Trials which met inclusion criteria were thalamic-pituitary-adrenal axis in association assessed for scientific rigour. Data were with rectal therapy has also been shown.2' 26 extracted by two independent observers Newer topically active corticosteroids such according to predetermined criteria. as tixocortol, beclomethasone, prednisolone Results-Of 83 trials retrieved, 33 met metasulphabenzoate, and budesonide, with inclusion criteria. Pooled odds ratios restricted absorption or rapid hepatic metab- (POR) showed conventional rectal corti- olism have been developed to reduce the costeroids and rectal budesonide to be adverse effects associated with conventional clearly superior to placebo.
    [Show full text]
  • Budesonide (Topical) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Budesonide (Topical) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Uceris Brand Names: Canada Entocort What is this drug used for? It is used to treat ulcerative colitis. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any other bowel problems. If you have an infection. If you have TB (tuberculosis), talk with your doctor. If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for HIV, infections, or depression. There are many drugs that must not be taken with this drug. Your doctor or pharmacist can tell you if you are taking a drug that Budesonide (Topical) 1/7 must not be taken with this drug. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems.
    [Show full text]
  • Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate May 2021
    Contains Nonbinding Recommendations Draft – Not for Implementation Draft Guidance on Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate May 2021 This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product. The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required. This is a new draft product-specific guidance for industry on generic fluticasone furoate; umeclidinium bromide; vilanterol trifenatate.
    [Show full text]
  • TRELEGY ELLIPTA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypercorticism and adrenal suppression may occur with very high These highlights do not include all the information needed to use dosages or at the regular dosage in susceptible individuals. If such TRELEGY ELLIPTA safely and effectively. See full prescribing changes occur, discontinue TRELEGY ELLIPTA slowly. (5.8) information for TRELEGY ELLIPTA. • If paradoxical bronchospasm occurs, discontinue TRELEGY ELLIPTA and institute alternative therapy. (5.10) TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol • Use with caution in patients with cardiovascular disorders because of inhalation powder), for oral inhalation use beta-adrenergic stimulation. (5.12) Initial U.S. Approval: 2017 • Assess for decrease in bone mineral density initially and periodically --------------------------- RECENT MAJOR CHANGES --------------------------- thereafter. (5.13) Indications and Usage, Maintenance Treatment of Asthma (1.2) 9/2020 • Glaucoma and cataracts may occur with long-term use of ICS. Worsening Dosage and Administration, Recommended Dosage for 9/2020 of narrow-angle glaucoma may occur. Use with caution in patients with Maintenance Treatment of Asthma (2.3) narrow-angle glaucoma and instruct patients to contact a healthcare Contraindications (4) 9/2020 provider immediately if symptoms occur. Consider referral to an Warnings and Precautions, Serious Asthma-Related Events – 9/2020 ophthalmologist in patients who develop ocular symptoms or use Hospitalizations, Intubations, Death (5.1) TRELEGY ELLIPTA long term. (5.14) Warnings and Precautions, Effect on Growth (5.18) 9/2020 • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct --------------------------- INDICATIONS AND USAGE ---------------------------- patients to contact a healthcare provider immediately if symptoms occur.
    [Show full text]
  • Fluticasone Furoate, Umeclidinium and Vilanterol (Trelegy)
    pat hways Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 Key points The content of this evidence summary was up-to-date in June 2018. See summaries of product characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA (summary of product characteristics). Overview This evidence summary discusses 2 randomised controlled trials (RCTs) looking at the safety and efficacy of fluticasone furoate/umeclidinium/vilanterol (an ICS/LAMA and LABA combination inhaler) in people with COPD who were symptomatic despite regular maintenance treatment and who either had a history, or were at risk, of exacerbations. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 54 Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18) Fluticasone furoate/umeclidinium/vilanterol (Trelegy) is licensed for maintenance treatment of adults with moderate-to severe COPD who are not adequately treated by a combination of an ICS and a LABA. Fluticasone furoate/umeclidinium/vilanterol has been shown to reduce the annual rate of moderate or severe exacerbations by 15% compared with fluticasone furoate/vilanterol.
    [Show full text]